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A strong effect of individual compliance
with mass drug administration for lymphatic
filariasis on sustained clearance
of soil‑transmitted helminth infections
Jérémy T. Campillo1 , Naomi P. Awaca‑Uvon2, Jean‑Paul Tambwe2, Godefroy Kuyangisa‑Simuna2,
Johnny Vlaminck3, Gary J. Weil4, Michel Boussinesq1, Cédric B. Chesnais1 and Sébastien D. S. Pion1*

Abstract
Background: The impact of semiannual mass drug administration (MDA) with albendazole (ALB; 400 mg) alone on
lymphatic filariasis (LF) and soil-transmitted helminth (STH) infections was assessed during two trials conducted from
2012 to 2018 in the Republic of Congo and the Democratic Republic of Congo. The collected data were analyzed to
evaluate the effect of compliance with ALB treatment on STH infections.
Methods: STH infections were diagnosed with duplicate Kato-Katz thick smears and the results are reported as eggs
per gram of stool. All subjects with at least two STH infection assessments were included in the analyses. We used
parametric survival models to assess the influence of compliance with ALB treatment on the probability of (i) achiev‑
ing sustained clearance of an STH infection, and (ii) acquiring an STH infection during the follow-up.
Results: Out of 2658 subjects included in the trials, data on 202 participants (701 person-years; PY) with hookworm
infection, 211 (651 PY) with Ascaris lumbricoides infection and 270 (1013 PY) with Trichuris trichiura infection were
available to calculate the probability of achieving sustained clearance of infection. The effect of ALB was dose related
for all three STH. For hookworm, the time required for sustained clearance was longer (4.3 years, P < 0.001) for partici‑
pants who took zero doses per year and shorter (3.4 years, P = 0.112) for participants who took two doses per year
compared to those who took one dose per year (3.7 years). For Ascaris, the time required to obtain sustained clear‑
ance followed the same pattern: 6.1 years (P < 0.001) and 3.2 years (P = 0.004) vs 3.6 years for, zero, two and one dose
per year, respectively. For Trichuris, less time was required for sustained clearance (4.2 years, P < 0.001) for fully compli‑
ant participants, i.e. those who took two doses per year, than for those who only took one dose per year (5.0 years).
ALB was more effective in achieving sustained clearance of STH infection in subjects with light baseline infection
intensities compared to those with higher egg counts.
Conclusion: Our results illustrate the importance of MDA compliance at the level of the individual with respect to
the STH benefit provided by semiannual ALB MDA, which is used for the elimination of LF in Central Africa.
Keywords: Soil-transmitted helminths, Albendazole, Parametric survival analysis, Treatment adherence, Mass drug
administration
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Background
Soil-transmitted helminth (STH) infections are among
the most common infections in the world and affect
poor and disadvantaged communities, particularly in
sub-Saharan Africa, Southeast Asia and Latin America.
In 2010, it was estimated that 438.9 million people were
infected with hookworm, 819.0 million with Ascaris
lumbricoides and 464.6 million with Trichuris trichiura
[1]. The current strategy used to control STH infections
is to conduct periodical deworming campaigns without individual diagnosis that target at-risk populations
in endemic areas (preschool children, school-age children, women of reproductive age and adults in certain
high-risk occupations). The World Health Organization
(WHO) recommends the use of benzimidazoles: albendazole (ALB; 400 mg) or mebendazole (500 mg). Because
of logistic and cost constraints, preventive chemotherapy
campaigns for STH are usually conducted once or twice
per year, depending on the initial prevalence of infection with any STH [2]. However, the optimal frequency
of administration to maximize impact remains a topic of
discussion [3]. In this study, we had the opportunity to
assess the individual effect of a semiannual ALB treatment on STH infections. The data originate from two
community trials that were designed to evaluate the
effect of mass drug administration (MDA) with semiannual ALB on lymphatic filariasis (LF) in two countries in
central Africa. The first study was conducted in a village
in the Republic of the Congo (Congo), where A. lumbricoides infection prevalence decreased significantly
from 56.5% to 12.9% and T. trichiura infection prevalence decreased significantly from 78.6% to 59.4% after
7 rounds of ALB MDA with global treatment adherence
between 83 and 90% [4]. The second study took place
in two contiguous villages in the Democratic Republic
of the Congo (DRC), where hookworm infection prevalence decreased significantly from 58.6% to 21.2% after
eight rounds of ALB MDA with a global treatment adherence of between 56 and 88%; Ascaris and Trichuris infection prevalences also decreased (from 14.0% to 1,6% and
from 4.1% to 2.9%, respectively) [5]. The results of these
two trials are consistent with those previously observed
regarding ALB efficacy: according to a meta-analysis
of more than 50 clinical trials, ALB has very good efficacy for clearing hookworm infections, good efficacy for
Ascaris infections, but only moderate efficacy for Trichuris infections [6].
Some studies have shown that semiannual ALB MDA
is highly effective for reducing STH prevalence at the
community level [4, 5, 7–10]. However, considerable
heterogeneity has been observed at the individual level,
and no prior studies have examined the impact of the
compliance of individuals with MDA on their STH
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infections. For example, in one study, infections cleared
in some individuals after a single treatment, while
infections were still present in others (due to persistence or reinfection) after eight rounds of semiannual
MDA [11]. In the present study, we used longitudinal
treatment and parasitology data collected between
2012 and 2018 from two community MDA studies to
assess relationships between MDA compliance by individuals with STH infections and their subsequent infection status. The results indicate a clear link between
MDA compliance by individuals and sustained clearance of STH infections.

Methods
Study population

The design of the MDA studies has been described
elsewhere [4, 5]. In Congo, the study was conducted
from 2012 to 2015 in Seke-Pembe, a village located in
Mabombo health district (Bouenza division). In the
DRC, the study site consisted of two neighboring villages (Mbunkimi and Misay) located in Kwilu province,
and the trial took place from 2014 to 2018. Study participants were tested for STH infections at baseline and then
annually. No deworming program had ever been conducted in the two areas prior to our trials. Both studies
were approved by ethics committees and administrative
authorities in the respective countries. Adult participants signed an informed consent form. Participants
aged < 18 years were enrolled only after verbal assent and
if one parent signed a consent form.
During the course of the two trials, a total of 2658 individuals were examined at least once for LF, and a total of
1573 provided stool samples at least once.
Assessment of STH infections

Annual parasitological assessments were performed
for participants > 5 years of age. STH infections were
detected by microscopic examination of stool specimens.
Participants were given a 50-mL plastic stool container
and asked to collect a sample of their stool in the morning. The stool specimens were collected and stored in
cooling boxes and shipped within 6 h to the laboratory,
where they were immediately processed or stored overnight at 6 °C. Two thick smears were prepared according to the Kato-Katz method for each stool sample [12].
Thick smears were examined by microscopy at 40× magnification, and the slides prepared from each sample were
examined by two different microscopists. The arithmetic
mean egg count from the two slides was calculated, and
the results are expressed for each species as eggs per
gram of stool (EPG).
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Drug distribution and assessment of treatment adherence

All participants were offered treatment with one ALB
tablet (400 mg) that was swallowed under the direct
observation of study staff. All inhabitants who had
not participated in the parasitological survey or who
missed testing (due to absence or refusal) were later
visited at home and offered ALB treatment. All treatments were provided under the supervision of a local
healthcare worker who was also responsible for conducting a population census before each semiannual MDA.
Every treatment was recorded in a drug treatment register. In addition, participants were asked whether they
had received ALB during the previous MDA campaign
(6 months earlier) during annual parasitological surveys.
Therefore, for each annual parasitological assessment, we
determined if each participant had taken two, one or zero
ALB treatments since the last parasitological assessment.
Statistical analysis

The primary endpoint (i.e. event of interest) for the study
was conversion in STH infection(s). This was considered
separately for conversion from a positive to a negative
test during follow-up (defined as the sustained clearance
of infection analysis) and for conversion from negative to
positive (defined as the incident infection analysis).
The sustained clearance analysis included all individuals who were positive for A. lumbricoides, T. trichiura or
hookworm at the time of their first test (which was not
necessarily performed during the year when the trial
started at the site) who also had at least one subsequent
stool sample tested for STH. Therefore, individuals who
were negative at baseline and remained negative throughout their follow-up were not included in the analyses
(representing 59.1%, 47.8% and 37.6% of the population
with at least one follow-up test for hookworm, Ascaris
and Trichuris, respectively). The numbers of excluded
individuals are provided in Additional file 1: Table S1. A
sensitivity analysis including data on all the participants
who were positive at the time of their first test but who
had become negative by their follow-up, regardless of
whether they subsequently became positive again, is provided in Additional file 1: Table S2.
The incident infection analysis included all individuals who were negative for A. lumbricoides, T. trichiura
or hookworm at the time of their first stool test who had
a positive stool test at a later time point (regardless of
whether they subsequently became negative again).
We used survival analysis methods for the sustained
clearance and incident infection analyses. The start date
for the survival analysis was the first visit (index date)
with a positive STH test for the sustained clearance of
infection analysis or a negative STH test for the incident
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infection analysis. Individual observations were censored
at the end of the follow-up or at the date of the event
(date of the annual parasitological survey). Each participant’s data were considered for calculation of cumulative
person-years (PY) in the survival analysis.
We considered the following non-time-varying covariates for each STH analysis: sex and initial EPG intensity
(categorized according to WHO guidelines [13]). We also
considered the following time-varying covariates: age
(categorized according to interquartile and median values—5–8, 9–12, 13–30 and ≥ 31 years old); and the number of ALB tablets taken during the previous year (0, 1 or
2).
Univariate analysis of infection status conversion rates
was conducted using Mantel–Haenszel tests. We used
parametric survival models with accelerated failure
time to estimate the influence of time-varying variables
on infection status conversion (time-to-event) [14, 15].
These models allow longitudinal analyses with time-varying variables; they are more informative and provide time
ratios that enable prediction of mean time until an event
occurs (either sustained clearance or incident infection
events).
Several time distributions that do not require meeting
the proportional risk assumption were tested according to the Akaike information criterion (AIC). Random
effects at the household and at the village level were
assessed in all survival models, and significance was
assessed using the results of likelihood ratio tests. Significant random effects were retained in the models. Results
are presented as time ratios with 95% confidence intervals (CI). Time ratios represent time differences to event
(individual infection status conversion) according to the
reference category. Sociodemographic data, occupation,
initial infection intensity and the number of ALB tablets
taken per year were included in the Ascaris, Trichuris and
hookworm infection status conversion survival models.
For the Trichuris model, the variable Numbers of ALB
tablets taken per year had only two categories (1 or 2)
because only 1 PY contributed to the zero-dose category.
Predicted average times to infection status conversions
were estimated using the command margins in STATA
v.15.1 software (StatCorps, College Station, TX) [16].
For individuals for whom sustained clearance of infection was achieved, mixed models with random effects
were used to describe changes in EPG according to time,
treatment history and sociodemographic information
for each STH infection. Several transformations (linear,
quadratic, first-order fractional polynomials and secondorder fractional polynomials) were tested for the time
variable, and selection was made according to AIC. Random effects at village level were considered for the parametric survival analysis and mixed models for changes in
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EPG. Lastly, the significance of relevant interaction terms
was assessed (age and sex, age and initial infection intensity, age and number of ALB treatments taken, sex and
initial infection intensity, sex and number of ALB treatments taken) for all models. All analyses were performed
using STATA v.15.1 software.

Results
Study participants

For the sustained clearance model, repeated observations
were made for the hookworm infection analysis for 202
of 2658 participants enrolled in the studies (7.6%), with
701 PY of observations. Stool examinations were negative for hookworm for 135 of these participants (66.8% of
individuals diagnosed with hookworm infection at their
first parasitological exam) during the course of the study,
which remained the case until their last follow-up visit.
For Ascaris, there were longitudinal data for 211 (7.9%)
participants for analysis, with 681 PY of observations.
In 172 of these participants (81.5% of individuals with
Ascaris at their first parasitological exam), stool samples became negative during the course of the study and
remained so until their last follow-up visit. For Trichuris,
there were baseline and follow-up data for 270 participants (10.2% of all study participants) for the analysis,
with 1,019 PY of observations. Of these participants, 85
(31.5% of individuals with a Trichuris infection at their
first parasitological exam) became negative during the
course of the study and remained so until their last follow-up visit. The key infection survival data are summarized in Table 1 along with results of a bivariate analysis
of co-factors. Of note, most individuals with hookworm
infection lived in the DRC study site, whereas most individuals with Ascaris and Trichuris infections lived in the
Congo study site.
For the incident infection model, out of 542 individuals
negative for hookworm at baseline with at least one follow-up visit, 102 (220 PY) experienced an incident infection (18.8%). For Ascaris, out of 533 participants negative
at baseline with at least one follow-up visit, 177 (727 PY)
experienced an incident infection (33.2%). For Trichuris,
out of 474 participants negative at baseline with at least
one follow-up visit, 194 (772 PY) experienced an incident
infection (40.9%).
Bivariate analysis of sustained clearance of STH infection

The unadjusted sustained clearance rates for hookworm,
Ascaris and Trichuris infections were 19.2, 25.2, and 8.4
events per 100 PY of observation, respectively (Table 1).
Table 1 also shows sustained clearance rates adjusted
for each covariable. Because the number of ALB tablets taken per year is a time-varying variable, it was not
included in the sustained clearance rate calculations.
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For hookworm and Ascaris, the probability of sustained
clearance was higher for females than for males. Older
individuals converted to negative more often than children for all three STH infections. Despite low numbers of
participants with heavy worm loads in the earlier years of
the study, the initial intensity of infection was negatively
correlated with the probability of sustained clearance for
Ascaris and Trichuris. Finally, the probability of sustained
clearance varied by village of residence.
Parametric survival multivariate models for sustained
clearance of STH infection

Parametric survival model results for sustained clearance
are presented in Table 2. For the hookworm and Ascaris
models, a log-normal distribution gave the best fit to the
data, whereas a log-logistic distribution was a better fit
for Trichuris. No significant interactions between the
covariates were found. Household random effects were
included for the Trichuris model [intraclass correlation coefficient (ICC) 12.2%, P = 0.002]. Village random
effects were included for the hookworm model (ICC
18.0%, P < 0.001). Random effects were not significant for
the Ascaris model. For hookworm, Ascaris and Trichuris,
older individuals (> 30 years of age) achieved sustained
clearance more rapidly than children aged 5–8 years (3.3
vs 5.7 years for hookworm; 3.1 vs 3.8 years for Ascaris
and 4.1 vs 4.7 years for Trichuris, respectively). It took
significantly longer for non-compliant individuals (zero
doses per year) to achieve sustained clearance for Ascaris
or hookworm than for individuals who took one dose
per year [6.1 vs 3.6 years for Ascaris (P < 0.001) and 4.3 vs
3.7 years for hookworm (P < 0.001), respectively]. In addition, it took less time to achieve sustained clearance of
Ascaris and Trichuris infection in individuals who were
highly compliant with MDA (two doses per year) compared to individuals who took only one dose per year [3.2
vs 3.6 years for Ascaris (P = 0.004) and 4.2 vs 5.0 years for
Trichuris (P < 0.001), respectively].
Figure 1 illustrates that, for all three STH infections,
the predicted proportion of participants who experienced
sustained clearance of infection was higher in highly
compliant individuals and increased with the duration
of follow-up. Figure 1 also shows that in individuals with
low compliance, sustained clearance was observed after
2 and 3 years of follow-up for hookworm and Ascaris
infection, respectively, whereas this started after 1 year in
fully compliant individuals.
Regarding infection intensity, it took significantly
longer to achieve sustained clearance in individuals
with moderate to heavy initial infection intensity with
Trichuris (≥ 1000 EPG) than in individuals with light
infections (< 1000 EPG) (4.2 vs 5.0 years, respectively).
Baseline infection intensities did not significantly affect

135

155

13–30 Years

≥ 31 Years and more

29

16

323

336

42

Moderate

Heavy

Misay

Mbunkimi

Seke Pembe

575

166

Light

245

8–12 Years

311

Female

5–8 Years

390

701

PY

18

56

61

0

4

131

42

24

39

30

66

69

135

No. of events

42.8

16.7

18.9

0

13.8

20.0

27.1

17.8

23.5

12.2

21.2

17.7

19.2

Rate

a

Hookworm (202 individuals)

Male

All participants

Categories

27.0–68.0

12.8–21.6

14.7–24.3

N/A

5.2–36.5

16.8–23.7

20.0–36.6

11.9–26.5

17.2–32.2

8.6–17.5

16.7–27.9

14.0–22.4

16.2–22.8

95% CI

0.001

0.059

0.009

0.023

P

596

41

44

38

374

269

222

117

189

153

382

299

681

PY

Infection status conversion rate (for 100 PY)

25.3

31.7

18.2

21.0

23.3

28.6

33.3

27.3

24.3

13.1

28.5

21.1

25.2

Rate

a

21.6–29.7

18.4–54.6

9.1–36.3

10.5–42.1

18.8–28.7

22.9–35.8

26.5–41.9

19.3–38.7

18.2–32.5

8.4–20.3

23.7–34.4

16.5–27.0

21.7–29.3

95% CI

0.247

0.022

0.001

0.017

P

994

20

3

16

369

634

387

209

222

201

599

420

1019

PY

80

4

1

1

11

74

54

16

9

7

50

36

86

No. of events

8.0

N/A

N/A

6.2

3.0

11.7

13.9

7.6

4.0

3.5

8.3

8.6

8.4

Ratea

Trichuris (270 individuals)

6.5–10.0

N/A

N/A

0.9–44.4

1.6–5.4

9.3–14.7

10.7–18.2

4.7–12.5

2.1–7.8

1.7–7.3

6.3–11.0

6.2–11.9

6.8–10.4

95% CI

< 0.001

< 0.001

0.919

P

According to World Health Organization (WHO) guidelines: for hookworm, 1–1999 (light), 2000–3999 (moderate), > 4000 eggs per gram of stool (EPG) (heavy); for Ascaris, 1–4999 (light), 5000–49,999 (moderate), >
49,999 EPG (heavy); for Trichuris, 1–999 (light), 1000–9999 (moderate), > 10,000 EPG (heavy)

b

a

PY Person-years, CI confidence interval

151

13

8

8

87

77

74

32

46

20

109

63

172

No. of events

Ascaris (211 individuals)

P is calculated from significance tests using the Mantel–Haenszel method based on stratified rate ratios

Village

Initial
infection
intensityb

Age

Sex

Variables

Table 1 Sustained clearance rates for hookworm, Ascaris and Trichuris infections
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Table 2 Results of parametric survival models for sustained clearance of hookworm, Ascaris and Trichuris infections (with random
effects)
Variables

Categories

Hookworm
TR/95% CI

Sex
Age

Initial infection intensityb
Treatment

Ascaris

Trichuris
a

TR/95% CI

P

P

Ref.

TR/95% CIa

P

Female

Ref.

Male

1.10 (1.01, 1.19)

5–8 Years

Ref.

8–12 Years

0.93 (0.83, 1.04)

0.223

0.95 (0.86, 1.08)

0.398

1.06 (0.91, 1.23)

0.452

13–30 Years

0.87 (0.77, 0.98)

0.019

0.86 (0.75, 1.00)

0.046

0.96 (0.83, 1.10)

0.557

More than 30 years

0.79 (0.70, 0.88)

< 0.001

0.81 (0.71, 0.92)

0.001

0.88 (0.77, 0.99)

0.049

Light

Ref.

Moderate to heavy

1.20 (0.98, 1.46)

0.072

1.06 (0.97, 1.16)

0.170

1.18 (1.07, 1.31)

Zero dose per year

1.16 (1.00, 1.35)

< 0.001

1.74 (1.28, 2.38)

< 0.001

Not calculable

0.020

1.11 (1.02, 1.21)

Ref.
0.013

Ref.

One dose per year

Ref.
0.91 (0.81, 1.02)

0.112

0.87 (0.79, 0.95)

Village

< 0.001

Not included

0.99 (0.92, 1.06)

0.807

Ref.

Ref.

Two doses per year
Random effects
Model

a

Ref.

Ref.

< 0.001

Ref.
0.004

0.84 (0.77, 0.91)

< 0.001

Household

0.002

ICC

18.0%

Distribution

Log normal

Log normal

12.2%
Log logistic

AIC

464.1

515.9

410.2

Log likelihood

− 222.0

− 249.0

− 196.1

Ref. Reference, ICC intraclass correlation coefficient, AIC Akaike information criterion; for other abbreviations, see Table 1
a

Adjusted time ratio (TR)/95% confidence intervals (CI). For example, for the Ascaris model, compared to a female (TR = 1), it took 11% (TR = 1.11) more time to
achieve sustained clearance in a male

b

According to WHO guidelines: for hookworm, 1–1999 (light), > 2000 EPG (moderate to heavy); for Ascaris, 1–4999 (light), > 5000 EPG (moderate to heavy); for
Trichuris, 1–999 (light), > 1000 EPG (moderate to heavy)

Fig. 1 a–c The influence of compliance with albendazole treatment on soil-transmitted helminth infection status in study participants with prior
infections. a Hookworm, b Ascaris, c Trichuris

the time to sustained clearance for Ascaris or hookworm
infections.
Parametric survival multivariate models of STH incident
infection

Parametric survival model results for incident infection
are presented in Table 3. A log-logistic distribution gave
the best fit for data in the hookworm and Trichuris models; a log-normal distribution provided the best fit for the

Ascaris model. No interactions between the covariates
were found. Household random effects were included
for the Trichuris model (ICC 42.9%, P < 0.001). Village random effects were included for the Ascaris models (ICC 45.7%, P < 0.001) and hookworm model (ICC
31.4%, P < 0.001). For hookworm and Trichuris, males
acquired infection significantly more slowly than females.
For the Trichuris model, older individuals (> 13 years)
acquired infection significantly faster than individuals
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Table 3 Results of parametric survival models for incident hookworm, Ascaris and Trichuris infections (with random effects)
Variables

Categories

Hookworm
TR/95% CI

Sex
Age

Treatment

Female

Ref.

Male

1.39 (1.11, 1.73)

5–8 Years

Ref.

Key survival data

P

TR/95% CI

0.004

1.10 (0.94, 1.19)

Trichuris
P

TR/95% CI

0.234

1.22 (1.031, 1.44)

Ref.

P

Ref.

Ref.

0.018

Ref.

8–12 Years

1.12 (0.87, 1.45)

0.361

1.07 (0.88, 1.32)

0.489

0.88 (0.73, 1.05)

0.156

13–30 Years

1.02 (0.72, 1.46)

0.872

1.13 (0.87, 1.46)

0.364

0.62 (0.46, 0.84)

0.002

More than 30 years

0.95 (0.70, 1.28)

0.738

1.11 (0.87, 1.41)

0.412

0.53 (0.40, 0.70)

< 0.001

Zero doses per year

0.79 (0.51, 1.22)

0.290

0.62 (0.42, 0.91)

0.001

0.78 (0.53, 1.13)

0.190

One dose per year

Ref.

Two doses per year

0.97 (0.70, 1.33)

0.828

1.10 (0.80, 1.50)

0.559

1.14 (0.85, 1.54)

0.385

Village

< 0.001

Village

< 0.001

Household

< 0.001

Random effects
Model

Ascaris

Ref.

Ref.

ICC

31.4%

45.7%

42.9%

Distribution

Log logistic

Log normal

Log logistic

AIC

505.5

626.5

718.4

Log likelihood

− 243.7

− 304.2

− 350.2

420

727

772

Number of subjects
PY

102

177

194

For abbreviations, see Tables 1 and 2

aged 5–8 years. Non-compliant individuals (zero doses
per year) acquired Ascaris infection significantly more
quickly than individuals who took one dose of ALB per
year.
Changes in EPG over time

Linear transformation of time provided the best fit for
the EPG data. No multilevel effects were included in
these mixed models because neither the village nor the
household effect was significant. Overall decreases in
EPG were superior in individuals with better compliance
(Table 4). For all three STH, the decline in EPG over time
was slower in younger individuals, regardless of the number of ALB tablets taken per year.
According to the mixed model, decreases in hookworm
EPG were not significantly different for individuals with
different compliance patterns: —81.2 EPG/year (95% CI
− 316.0–153.6) for one dose and − 197.1 EPG/year (CI
95% − 402.6–8.4) for two doses, compared with no treatment. Decreases in Ascaris EPG were significantly different between individuals who took zero and one dose per
year (regression coefficient: − 7076.1 EPG/year, CI 95%
− 13,103 to − 1048.9) and between those who took zero
and two doses per year (regression coefficient: -6,207.3
EPG/year, CI 95% − 1.2196 to − 218.5). Finally, decreases
in Trichuris EPG were not significantly different between
individuals who took two doses per year (regression coefficient: -207.5 EPG/year, CI 95% − 603.2–188.3) and
those who took one dose per year.

Discussion
ALB is widely known to be effective for the treatment of
STH infections. Community MDA with ALB can reduce
Ascaris and hookworm prevalence, but the effects on
Trichuris tend to be modest [6, 17]. This is the first longitudinal study to examine the effect of individual compliance with semiannual MDA with ALB alone, given
for the elimination of LF, on STH infections. We found
that good compliance with semiannual rounds of MDA
resulted in shorter times to achieve sustained clearance
of STH infections. This was likely due to a combination
of curing existing infections and curing incident infections during the follow-up period. This dose-related
effect was particularly strong for ascariasis. A similar pattern was observed for hookworm, although the difference
between one and two doses per year was not statistically
significant. This might indicate that reinfection is more
rapid for hookworm than for Ascaris. Further studies are
needed to validate this hypothesis. As individuals with
Trichuris infection in this study were generally compliant
with MDA, we were unable to compare times to infection
status conversion based on ALB intake. It is interesting
that some non-compliant individuals with hookworm or
Ascaris infections achieved sustained clearance, and that
this phenomenon was more common in the later years of
the study, as shown in Fig. 1. Although some spontaneous loss of infection was expected, particularly for light
infections, an increase in sustained clearance events in
later years might have been due to a reduced force of
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Table 4 Mixed model results for the evolution of EPG intensity
Variables

Categories

Hookworm
Coeff./95% CIa

Sex

Age

Female

Ref.

Male

65.8 (− 34.4, 166.0)

Ascaris
P

Coeff./95% CIa

0.199

1056.7
(− 1115.9, 3229.2)

0.681

− 4540.2 (− 7576.5,
− 1504.0)

5–8 Years

Ref.

8–12 Years

32.6 (− 122.6, 187.8)

13–30 Years

− 128.0 (− 274.1, 18.0) 0.086

− 6432.5( − 9910.3,
− 2954.8)

− 8030.3 (− 11035,
− 5024.5)

Light

Ref.
1155.4 (929.3, 1383, 5)

Heavy
Timec

Continuous

Annual treatment inter‑
action with timec

Zero doses

Ref.

Ref.

One dose

− 81.2 (− 316.0, 153.6) 0.498

Two doses

− 197.1 (− 402.6, 8.4)

− 7076.1 (− 13,103,
− 1048.9)

Intercept at baseline

a

Coeff./95% CIa

0.340

234.2 (− 139.1, 607.5)

0.003

126.1 (− 439.3, 691.6)

0.662

0.0001

− 333.9 ( − 929.6,
261.7)

0.272

< 0.001 − 498.6 (− 1179.8,
− 162.3)

0.010

Ref.

< 0.001 8727.8 (6302.6, 11153)

P

Ref.

Ref.

Moderate

Study site

P

Ref.

More than 30 years − 107.1 (− 251.4, 37.1) 0.088
Initial infection
intensityb

Trichuris

0.219

Ref.

Ref.

< 0.001 1061.2 (653.1, 1469.4)

< 0.001

3171.6 (2875.8, 3467.3) < 0.001 33, 843 (28637, 39050)

< 0.001 6886.7 (5518.5, 8254.9)

< 0.001

− 58.2 (− 263.2, 146.6) 0.577

0.582

− 91.9 (− 378.8, 195.0)

0.530

0.021

Ref.

− 6207.3 (− 12,196,
− 218.5)

0.042

− 207.5 (− 603.2, 188.3) 0.304

0.060

1631.5 (− 4174.5,
7437.4)

Not calculable

Bandundu

Ref.

Ref.

Seke Pembe

− 196.9 (− 427.8, 34.0) 0.095

2596.8 (− 1004.8,
6198.3)

0.158

721.0 (− 410.1, 1852.1)

Ref.

Zero doses

387.4 (− 478.5, 1253.2) 0.381

− 7884 − 33,495,
17,725.7)

0.546

Not calculable

One dose

272.7 (− 636.0, 1181.4) 0.556

22,598 (− 3365.0,
48,561)

0.088

− 199.5 (− 170.9,
1305.9)

0.795

Two doses

404.0 (− 439.6, 1247.7) 0.348

22,888 (− 2750.4,
48,527)

0.080

936.6 (− 192.0, 2065.1)

0.104

0.212

Adjusted regression coefficient (Coeff.)/95% CI

b

According to WHO guidelines: for hookworm, 1–1999 (light), 2000–3999 (moderate), > 4000 EPG (heavy); for Ascaris, 1–4999 (light), 5000–49,999 (moderate), >
49,999 EPG (heavy); for Trichuris, 1–999 (light), 1000–9999 (moderate), > 10,000 EPG (heavy)

c
Interpretation of the interaction variable: for the hookworm model, all else being equal, each participant’s EPG decreased by 58.2 each year; and all else being equal,
participants taking one dose and two doses per year, as compared to zero doses, showed a decrease in their EPG by 81.2 and 197.1 EPG per year, respectively

infection in study communities (due to a “herd treatment
effect”) as a result of MDA.
The use of random effects at the household level
improved the parametric survival model for Trichuris.
Continued infection in households due to non-compliance or shared poor sanitation might increase the risk of
reinfection for other household members who do comply with treatment. This would tend to increase the mean
time for the sustained clearance of infection. Additional
studies will be needed to test this hypothesis and to
understand why the same household effect was not seen
with hookworm or Ascaris infection.
It is interesting that incident infections were observed
for all three STH infections during the course of the
study despite community MDA. While most of these
were probably true incidence events, it is likely that some
of them were examples of pseudo-incidence, which may

occur if light infections are not detected in prior stool
samples.
Based on our analysis, good compliance with MDA
was most effective for preventing Ascaris infections. This
was because random household effects were significant
for the Trichuris incidence model and for the hookworm
incidence model. This means that a fraction of the incident infections for hookworm and Trichuris were due to
random household effects regardless of MDA compliance. Random effects set at the village level were significant for the hookworm sustained clearance model and
the Ascaris incident infection model. This suggests that
a significant proportion of these status conversions were
due to common village-specific effects related to sanitation and/or infection-promoting behavior.
Higher infection intensity was negatively associated
with sustained clearance for all three STH, but this only
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resulted in a significantly longer time to achieve sustained clearance for Trichuris. However, low baseline
frequencies of moderate or high infection intensities for
hookworm and Ascaris provided low statistical power
for assessing the effect of infection intensity for these
infections. For all models, a shorter time to sustained
clearance was associated with older age. This is consistent with higher reinfection rates in children due to their
behavior and exposure (e.g. frequent close contact with
other children, walking barefoot outdoors, and hand to
soil to mouth) relative to those of older people.
We used mixed models to study changes in infection intensity (EPG) over time according to the number
of ALB tablets taken per year for each STH. Only the
Ascaris model showed a greater decrease in EPG for
compliant participants. No significant differences were
found for EPG decrease and ALB compliance in the
hookworm and Trichuris models. This was probably due
to a lack of power because EPG trended down in regression models as compliance increased.
One limitation of this study is that results may have
been influenced by prevalence or participation bias. We
believe that prevalence bias is unlikely to have impacted
our results because fewer than 20% of the study population had taken ALB prior to our study. On the other
hand, participation bias cannot be excluded because participants with a high participation frequency in our study
may have had different characteristics (including MDA
adherence) than non-participants.
As previously reported, MDA and stool survey participation rates decreased over time in these community
MDA studies [5]. This was probably due to study fatigue
on the part of some community members. The results of
this study that show the clear benefits of compliance with
MDA may help social mobilization campaigns to increase
initial and sustained MDA adherence by individuals and
populations.

Conclusions
This study demonstrated a clear dose–response relationship between individual MDA adherence with semiannual ALB and sustained clearance of STH infection over
time. In other words, sustained clearance of STH infections was more likely to be achieved in individuals with
good MDA adherence. These results should be used in
social mobilization programs to publicize the fact that
semiannual MDA with ALB for the elimination of LF also
significantly contributes to the control of STH infections
in individuals and communities.
Abbreviations
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